title: A prospective, randomized trial evaluating the safety and efficacy of fibrin sealant in tubeless percutaneous nephrolithotomy.
abstract: OBJECTIVE
  We performed a prospective, randomized trial to assess the safety and efficacy of fibrin sealant in tubeless percutaneous nephrolithotomy.
  
  
  METHODS
  A total of 63 patients undergoing tubeless percutaneous nephrolithotomy were randomized to receive Tisseel vapor heated sealant at the end of the procedure. Fibrin sealant was instilled under direct vision in the nephrostomy tract at the end of the procedure. Patients younger than 14 years and those undergoing staged percutaneous nephrolithotomy or bilateral simultaneous percutaneous nephrolithotomy were excluded from study. Patients needing greater than 2 percutaneous tracts, those with significant bleeding or associated pyonephrosis and those with a residual stone burden were also excluded from study. The perioperative outcome in these patients (experimental group) was compared with the outcome in those undergoing tubeless percutaneous nephrolithotomy without fibrin sealant (control group).
  
  
  RESULTS
  Fibrin sealant was instilled in 32 patients. There was no difference in the hematocrit decrease and blood transfusion requirement in the 2 groups. Patients in the experimental group experienced less postoperative pain and required less analgesia. They were discharged home 5 hours earlier than patients in the control group. However, this difference was not statistically significant. Complete stone clearance was achieved in 87.5% of patients in the experimental group and in 90.32% of controls.
  
  
  CONCLUSIONS
  The instillation of Tisseel fibrin glue is safe for tubeless percutaneous nephrolithotomy. It is associated with less postoperative pain and a lower analgesic requirement. Additional prospective, randomized studies are required to better define its clinical role in the future.
authors.affiliation: R. G. Stone Urological Research Institute, Khar (W), and Tata Memorial Hospital, 21-A, 14-A Road, Ahimsa Marg, Mumbai 400052, India. drhemendrashah@yahoo.co.in
authors.forename: Hemendra N
authors.initials: HN
authors.lastname: Shah
authors.forename: Sunil
authors.initials: S
authors.lastname: Hegde
authors.forename: Jignesh N
authors.initials: JN
authors.lastname: Shah
authors.forename: Pradnya D
authors.initials: PD
authors.lastname: Mohile
authors.forename: Thyavihally B
authors.initials: TB
authors.lastname: Yuvaraja
authors.forename: Manish B
authors.initials: MB
authors.lastname: Bansal
mesh_terms: D000328:Adult; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use*; D006400:Hematocrit; D006417:Hematuria / Q000517:prevention & control; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009403:Nephrostomy, Percutaneous / Q000379:methods*; D010149:Postoperative Pain / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D015718:Fibrin Tissue Adhesive; D006490:Hemostatics